ThomasNet Home   |   Promote Your Business
Home  |   My ThomasNet News®  |   Industry Market Trends  |   Submit Release  |   Advertise  |   About Us May 26, 2012  

Guidewires help place catheters in coronary arteries.

Print | 
Email |  Comment   Share  
March 1, 2007 - Designed with single-piece steel core wire, REGATTA(TM) Steerable Guidewires feature hydrophilic coating technology that helps prevent swelling. REGATTA SB models include shaping ribbon that is oriented in plane of J-shape, helping physicians locate and access side branches, while REGATTA HS models feature rounded wedge tip that facilitates placement in highly narrowed arteries.

(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release

Cordis Corp.
14201 N.W. 60th Ave.
Hialeah, FL, 33014
USA



Cordis Corporation Launches Family of REGATTA(TM) Steerable Guidewires


With New Guidewires, Company Expands Product Portfolio to Fully Support Interventionalists and Patients

MIAMI LAKES, Fla., Feb. 20 /-- Cordis Corporation, a worldwide leader in developing and manufacturing interventional vascular technology, announced today the launch of the REGATTA(TM) Steerable Guidewire family in the United States. The launch is marked by the introduction this week of 12 selections of the REGATTA(TM) Steerable Guidewire and two choices of the REGATTA(TM) SB Steerable Guidewire. In April, the company will also add the REGATTA(TM) HS Steerable Guidewire in two selections.

Cordis is offering the REGATTA(TM) Guidewire family to provide tailored solutions for the placement of catheters and other interventional devices in coronary arteries. The REGATTA(TM) Guidewires are all-purpose guidewires; the REGATTA(TM) SB Guidewires are designed to facilitate access to side branches; and the REGATTA(TM) HS Guidewires include features that ease placement in highly narrowed arteries. The different selections for each version refer to variations in tip type, tip profile, lateral support and/or wire length.

"When I tested the REGATTA(TM) Guidewire family, I was pleased to see each of them perform well under challenging circumstances," said Emerson C. Perin, M.D., Ph.D., F.A.C.C., Director, New Interventional Cardiovascular Technology, Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, Texas. "It is good to see Cordis back in the cath lab with a strong and innovative line of steerable guidewires."

The launch marks a major milestone in the company's efforts to offer a comprehensive product portfolio to meet the needs of interventionalists and patients.

"With the REGATTA(TM) Guidewire family, we increase our ability to help physicians address the specific needs of patients," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Cardiology Division of Cordis Corporation.

All versions in the REGATTA(TM) Guidewire family feature a next-generation hydrophilic coating technology that prevents swelling and a single-piece steel core wire that enhances torque. In addition, the REGATTA(TM) Guidewires and the REGATTA(TM) HS Guidewires offer a unique microridge design for additional torque control. The REGATTA(TM) HS Guidewires also feature a rounded wedge tip that facilitates the introduction of the wire in highly narrowed lesions, and the REGATTA(TM) SB Guidewires come with an innovative shaping ribbon that is oriented in the plane of a J-shape, helping physicians locate and access side branches.

The U.S. launch of the REGATTA(TM) Guidewire family will be followed by market introductions outside the United States starting in a week. Cordis is the worldwide distributor of the REGATTA(TM) Guidewire family as a result of an agreement between Cordis and Brivant Limited signed in 2006.

About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, (NYSE:JNJ) is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease. For more information, visit http://www.cordis.com/.

CONTACT: Mariela Melendez of Cordis Corporation, +1-786-313-2776, cell, +1-786-218-4084, mmelen10@crdus.jnj.com; or Todd Ringler of Edelman, cell, +1-617-872-1235, todd.ringler@edelman.com, for Cordis Corporation

Web site: http://www.cordis.com/
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



Don’t hunt for stories like this.
Let Health, Medical and Dental Supplies & Equipment
Product News Come to You!
Get a Free Subscription
to Product News Alerts.
Start Your Free
Subscription to
Industry Market Trends.
 See more product news in:
Health, Medical and Dental Supplies and Equipment
 More New Product News from this company:
Stent System treats clogged neck arteries.
FDA-Approved Instruments treat clogged neck arteries.
Drug-Eluting Stent promotes smooth procedures.
Stent enables efficient bile duct treatment.
More ....
 Other News from this company:
Cordis Europe Signs Agreement with Volcano Europe to Provide Access to State-of-the-Art Intravascular Imaging for Use in Drug-Eluting Stent Procedures
New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty Procedures
Cordis Corporation Signs Definitive Agreement With Medinol for Global Distribution of Bare Metal Stents
Cordis Corporation Introduces DURA STAR(TM) Rx PTCA Dilatation Catheter
Cordis Corporation Launches Family of REGATTA(TM) Steerable Guidewires
More ....
 Tools for you
Watch Company 
View Company Profile
More news from this company
E-Mail Story
Save Story
Search for suppliers of
Medical Guidewires


Home  |  My ThomasNet News®  |  Industry Market Trends  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2012 Thomas Publishing Company
Terms of Use - Privacy Policy



Error close

Please enter a valid email address